Walgreens’ Pegus to present during colloquium session
DEERFIELD, Ill. — Cheryl Pegus, chief medical officer at Walgreens, will make a presentation during the 11th annual Population Health and Care Coordination Colloquium in Philadelphia next week.
Pegus, who was named the drug store chain’s chief medical officer last May, will present during the “Impact and Value of Pharmacist Interventions in Different Settings” session, which will examine the growing role pharmacists are playing in improving clinical outcomes through interventions at community pharmacies and employer worksite health clinics, Walgreens said.
The news followed Walgreens’ announcement that it now is a member of Care Continuum Alliance, an alliance of more than 200 stakeholders providing services across the continuum of care — from wellness and prevention to chronic condition management and complex care management.
Back in January, Pegus spoke at the Consumer Electronics Show in Las Vegas and highlighted the increasing role of mobile technology in health care.
“Leveraging our unmatched national footprint and 70,000 affiliated healthcare providers to provide access to care and [helping to] address the challenge of chronic care management are two key areas of strategic focus for Walgreens,” Pegus said at CES earlier this year. “By using technology to improve the patient experience and coordination of care, we can continue to improve measurable outcomes, adherence and quality, while also providing cost-effective care.”
UltiMed introduces 50-count needles offering for diabetes patients
ST. PAUL, Minn. — UltiMed is offering 50-count pen needles for patients with diabetes, the company announced.
The company said the needles would give diabetes patients a high-quality and cost-effective option for their pen needle supplies. Before, pen needles were dispensed in quantities of 100.
UltiMed said its needles, manufactured in its De Smet, S.D., factory, are the only ones assembled in the United States.
Salix issued CRL for Xifaxan
RALEIGH, N.C. — The Food and Drug Administration declined to approve a drug made by Salix Pharmaceuticals for irritable bowel syndrome, Salix said Tuesday.
The FDA issued a complete response letter to Salix for Xifaxan (rifaximin), a treatment for nonconstipation IBS and IBS-related bloating. Salix said it had anticipated that it would receive the letter based on an understanding that the agency needed more information related to retreatment.
A complete response letter indicates that the FDA has completed review of a regulatory approval application, but issues remain that preclude final approval. Salix said it planned to request a meeting with the agency to discuss the drug.